Faculty

Clinical Summary

Clinical Interests

• General Pulmonology
• Tracheostomy/ Ventilator
• Bronchopulmonary Dysplasia (BPD)
• Asthma
• Primary Ciliary Dyskinesia
• Sickle Cell Lung Disease
• Rare Lung Disease

Bio

Samuel Goldfarb, MD, is the Director of the Pediatric Cystic Fibrosis Program and CoDirector of the University of Minnesota Cystic Fibrosis Center. He is a Professor of Pediatrics at the University of School of Medicine. Dr. Goldfarb is the holder of the Annalisa Marzotto Endowed Chair in Cystic Fibrosis Care.

A graduate of Tel Aviv University Medical School, Dr. Goldfarb completed his pediatric internship and residency at Bridgeport Hospital, Yale University, CT. He continued his specialty training at the Children's Hospital of Philadelphia with a fellowship in pediatric pulmonology and continued as a faculty member at the Children's Hospital of Philadelphia until February 2021 when he joined the University of Minnesota.

Dr. Goldfarb maintains a special interest in the treatment of children with cystic fibrosis, interstitial lung disease, early and late pulmonary complications of oncology therapy, and pulmonary involvement of rheumatological disorders.

Dr. Goldfarb serves as the Chair of the American Thoracic Society Special Interest Group "Pulmonary Complications of Childhood Cancer Therapy" participating in the development of standardized care protocols and developing several multi-center clinical studies. He is also a member of the American Thoracic Society, the Rare Diffuse Pediatric Lung Disease Consortium, and the Therapeutic Development Network (TDN) for the Cystic Fibrosis Foundation.

Dr. Goldfarb is an active clinical researcher after a decade of NIH supported research in pediatric lung transplantation he has turned his attention to research in patients with Cystic Fibrosis while continuing his research in patients with pulmonary disease after bone marrow transplants. Dr. Goldfarb began his career as a basic science researcher working to better understand CFTR function and its interaction with chaperone proteins which can enhance abnormal CFTR function. He has continued throughout his career in clinical research and has been part of the TDN research network, most recently becoming the University of Minnesota Pediatric TDN director. Dr. Goldfarb is very active in ongoing research with CFTR modifier medications.

Clinical Summary

Clinical Interests:

• Severe Asthma
• Pulmonary causes of Pulmonary Hypertension
• Airway and Bronchoscopy
• Trach/Vent and Technology Dependence
• General Pulmonary 

Bio

Dr. Pianosi is Canadian by birth, of Italian origin, and thus hold multiple citizenships. He obtained his MD from the University of Toronto, completed a pediatric residency at the University of Ottawa (Children's Hospital of Eastern Ontario), and pediatric respiratory medicine fellowship at McGill University (Montreal Children's Hospital.

After his training, he went on to become an Assistant Professor of Pediatrics and Child Health at the University of Manitoba, then Associate Professor with tenure at Dalhousie University in Halifax, Nova Scotia. After practicing in Canada for 15 years, he moved to the Mayo Clinic in Rochester, Minnesota where he practiced for another 12 years, reaching Full Professor level in Pediatric and Adolescent Medicine.

In April of 2017 he moved to King's College Hospital, where he spent a little more than a year, but eventually opted to return to the University of Minnesota where he believed he would have the best opportunity to pursue research in an existing exercise testing lab for pediatric subjects.

Research Summary

In recent years, I have turned my attention to studying the clinical problem of dyspnea in children and adolescents. I see many patients with this complaint in clinic, and it turns out that approximately 1/4 patients with POTS report dyspnea as a prominent and sometimes disabling symptom. I have begun collaboration with an expert in cardiovascular pathophysiology in POTS out of New York Medical College. Nevertheless, the overarching theme of my recent work is dyspnea during exercise, to wit I created and validated pictorial, pediatric dyspnea scales. I wish to understand mechanisms of exertional dyspnea in children and adolescents - both those with cardiopulmonary disease and healthy subjects.

Clinical Summary

Asthma; CF; chronic lung disease of prematurity